Archive


Category: CNS Programs

  • Takeda Amend its Collaboration with Wave Life Sciences to Advance CNS Programs

    Shots: Wave to receive $22.5M for research & preclinical expenses and is eligible to receive opt-in payment, development & commercial milestone & will lead the manufacturing & joint clinical co-development activities. Both companies will share global costs & 50:50 profits Takeda’s gets an option to co-develop & co-commercialize CNS therapies for 3 targets, C9orf72, HTT […]